The 6th edition of the Hyderabad Property Show will start at the Hitex Exhibition Center here on March 2.
The 3-day belongings show will collectively convey a hundred and twenty developers throughout the city, stated S Ram Reddy, President of the Confederation of Real Estate Developers Associations of India (CREDAI), Hyderabad.
T changed into an eventful week for pharmaceutical and healthcare organizations. While traits at Fortis kept unfolding, the government made a few exciting movements on the regulatory front, mentioning public hobby.
The government has announced a major rejig of the Central Drugs Standard Control Organization (CDSCO), an Indian drug regulator that offers approvals and video display units for drug fines.
The authorities extended S Eswara Reddy as the new Drugs Controller General of India (DCGI) and relieved GN Singh with the spot effect from the post. GN Singh became DCGI in 2012.
Reddy, the first insider to be named DCGI, labored as Joint Drugs Controller before the elevation. His appointment as DCGI can be effective for three months until an often-appointed person takes the price.
CDSCO accompanied the latest DCGI by switching 42 drug inspectors and technical officers, many from CDSCO’s headquarters, to various zones throughout India.
Deputy drug controllers from the crucial west area, including R Chandrashekhar, have been transferred to the Goa subregion and A Ramkishan to the East Zone, Kolkata. They will be replaced by PBN Prasad and Rubina Bose from CDSCO headquarters. The authorities stated the shake-up was effected to strengthen the various zones and subzones.
The Indian government has been drawing flak on the quality of medication offered inside the country. Its research found that patients have circulated and eaten up by substandard pills and capsules not examined sufficiently for safety and stability.
The government, on its part, is attempting to reinforce the regulatory organization by hiring more fantastic inspectors and technical officers, developing potential through schooling and conducting joint inspections, and sharing information with US and UK drug regulators on first-class practices.
